<DOC>
	<DOCNO>NCT01019863</DOCNO>
	<brief_summary>Evaluation efficacy , tolerance , quality life cost effectiveness association Oxaliplatin , Gemcitabine , Rituximab Dexamethasone treatment patient refractory relapse non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Study Evaluate Oxaliplatin-based Chemotherapy Patients With Resistant Relapsing Non-Hodgkin Lymphoma .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Patients 18 year time inclusion . 2 . Documented CD20+ NHL , refractory relapse first line chemotherapy . 3 . No contraindication Oxaliplatin , Gemcitabine , Dexamethasone Rituximab . 1 . Other type nonHodgkin lymphoma 2 . Pregnancy lactation . 3 . Patient unable give write informed consent . 4 . Contraindication ou intolerance component RGDOx chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>